Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Limited history available
MDLN PEG Ratio has fewer than three reported periods, so a trend chart would be misleading.
PEG RATIO
N/A
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
N/A
PEG RATIO AVG 5Y
N/A
PEG RATIO AVG 10Y
N/A
PEG RATIO AVG 15Y
N/A
PEG RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$30.72B
PEG Ratio
4.14
TTM Avg
2.27
3Y Avg
2.27
5Y Avg
1.52
Market Cap
$28.62B
PEG Ratio
8.96
TTM Avg
5.67
3Y Avg
4.53
5Y Avg
3.90
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medline Inc. (MDLN) | $33.22B | N/A | N/A | N/A | N/A |
| Zoetis Inc. (ZTS)vs › | $32.40B | 2.04 | 2.96 | 3.83 | 3.78 |
| DexCom, Inc. (DXCM)vs › | $32.20B | 0.67 | 19.51 | 10.66 | 8.56 |
| Centene Corp. (CNC)vs › | $30.74B | N/A | 0.18 | 0.16 | 0.16 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.72B | 4.14 | 2.27 | 2.27 | 1.52 |
| ResMed Inc. (RMD)vs › | $30.60B | 0.72 | 1.36 | 1.45 | 1.33 |
| Biogen Inc. (BIIB)vs › | $29.99B | N/A | 0.34 | 0.24 | 0.23 |
| Mettler-Toledo International Inc. (MTD)vs › | $28.62B | 8.96 | 5.67 | 4.53 | 3.90 |
| IQVIA Holdings Inc. (IQV)vs › | $38.68B | 6.34 | 8.50 | 5.12 | 3.87 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $27.44B | N/A | 1.85 | 3.49 | 3.16 |
PEG Ratio
N/A
P/E Ratio
32.3
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.07 |
